Faeth Therapeutics, a San Francisco, CA-based cancer metabolism company, raised $47M in Series A funding.
The round, which brings total funding to date to $67m, was led by S2G Ventures, with participation from Khosla Ventures, Future Ventures, Digitalis, KdT Ventures, AgFunder, and Cantos.
The company intends to use the funds to advance its clinical trials that combine nutrient control, therapeutics and digital tools to inhibit cancer metabolism. The proceeds of the round will be used to support early phase clinical trials focusing on the safety of its approaches in cancer patients. Additionally, the funds will support the development of novel preclinical pipeline with its discovery platform, MetabOS™, which combines machine learning and functional genomics to uncover the precise nutrient vulnerabilities for a tumor based on genotype, organ of origin, and therapy,
Led by CEO Anand Parikh and Chief Scientific Officer Oliver Maddocks, Faeth Therapeutics leverages an approach that includes precisely targeted nutrient control, therapeutics, and digital tools to support both the patient and clinician. Preclinical studies in organoid and mouse models demonstrate that precise control of molecules, including amino acids and sugar, can reduce tumor size and suppress growth to a similar extent as standard-of-care chemotherapies, and combining nutrient control with drugs is significantly more efficacious than either intervention alone. The company has now moved to first-in-human clinical trials looking at pancreatic, colon, endometrial and ovarian cancers.
Faeth’s founding team also includes Sid Mukherjee, a Pulitzer Prize-winning oncologist and professor at Columbia University Irving Medical Center, and Lew Cantley, former Director of the Meyer Cancer Center at Weill Cornell Medicine and now a professor at the Dana-Farber Cancer Institute
FinSMEs
30/06/2022